Selected article for: "antiviral activity and limited activity"
Author: Denisa Bojkova; Jake E. McGreig; Katie-May McLaughlin; Stuart G. Masterson; Marek Widera; Verena Krähling; Sandra Ciesek; Mark N. Wass; Martin Michaelis; Jindrich Cinatl
Title: SARS-CoV-2 and SARS-CoV differ in their cell tropism and drug sensitivity profiles
  • Document date: 2020_4_5
    • ID: gpr86lxe_35
    Snippet: both SARS-CoV-2 and SARS-CoV CPE formation. In contrast to aprotinin, camostat, 429 . CC-BY-NC-ND 4.0 International license author/funder. It is made available under a The copyright holder for this preprint (which was not peer-reviewed) is the . https://doi.org/10.1101/2020.04.03.024257 doi: bioRxiv preprint and nafamostat exerted limited activity against double-stranded RNA formation in 430 SARS-CoV-2-infected cells. This may indicate that camos.....
    Document: both SARS-CoV-2 and SARS-CoV CPE formation. In contrast to aprotinin, camostat, 429 . CC-BY-NC-ND 4.0 International license author/funder. It is made available under a The copyright holder for this preprint (which was not peer-reviewed) is the . https://doi.org/10.1101/2020.04.03.024257 doi: bioRxiv preprint and nafamostat exerted limited activity against double-stranded RNA formation in 430 SARS-CoV-2-infected cells. This may indicate that camostat and nafamostat rather 431 exert cytoprotective effects that prevent cells from virus-induced lysis but less 432 pronounced antiviral activity. The mechanisms underlying the enhanced anti-SARS-433

    Search related documents:
    Co phrase search for related documents
    • antiviral activity and CPE formation: 1, 2, 3, 4, 5
    • antiviral activity and double strand: 1, 2
    • antiviral activity and limited activity: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18
    • antiviral activity and RNA formation: 1, 2, 3, 4, 5, 6, 7, 8
    • antiviral activity and SARS cell: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73
    • antiviral activity and virus induce: 1, 2, 3, 4
    • cell prevent and CPE formation: 1
    • cell prevent and double strand: 1
    • cell prevent and SARS cell: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23
    • cell prevent and virus induce: 1
    • CPE formation and RNA formation: 1
    • CPE formation and SARS cell: 1
    • CPE formation and SARS CoV SARS CPE formation: 1, 2
    • CPE formation and virus induce: 1
    • double strand and limited activity: 1
    • double strand and RNA formation: 1
    • double strand and SARS cell: 1, 2
    • double strand and virus induce: 1
    • double strand RNA formation and RNA formation: 1